COVID-19 Testing System Disrupted Resulting from Roche’s Supply Chain Glitch
Roche, a Swiss pharmaceutical company, was hit today (10/7) with a glitch that disrupted one of its warehouses. This interruption caused one of their main receivers, Britain’s National Health Service, to delay the reporting of nearly 16,000 positive COVID-19 tests....
COVID-19 Antibody Treatment Expansion Following Safety Clearance
GlaxoSmithKline (GSK) and Vir Biotechnology are partnering to conduct trials on an antibody for COVID-19 treatment. The clinical trial will include 1,300 patients globally and a control group receiving a placebo. Various other companies, Regeneron for instance, have...
Nvidia Building Britain’s Most Powerful Supercomputer to Combat COVID-19
Nvidia, a chip industry giant from the U.S., announced today (10/5) that they will be building a supercomputer called Cambridge-1 which will channel artificial intelligence technologies to help researchers find solutions to urgent medical challenges such as COVID-19....
Despite Advisory Committee’s Approval, FDA Rejects Mesoblast’s Ryoncil
Today (10/2) the U.S. Food and Drug Administration (FDA) announced the rejection of Ryoncil, a treatment for steroid-refractory acute graft versus host disease (SR-aGVHD) in pediatric patients. For patients with the most aggressive form of SR-aGVHD, the mortality rate...
Safety Report Review Calls for More Thorough Adverse Event Reporting by FDA
According to an analysis published in JAMA Internal Medicine, almost half of the Medical Device Reports (MDRs) were directly from the Medical Device Safety Communications (MDSC) sent by the U.S. Food and Drug Administration (FDA). From this report, it was more clear...
Premier Holographic Cardiac Ablation System by SentiAR Cleared by FDA
Today (9/30) the U.S. Food and Drug Administration (FDA) granted clearance for leading visualizations for surgical procedures provider, SentiAr’s holographic cardiac ablation system Command EP. This will be the first holographic guidance system to be used in an...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com